KINGSTON, Jamaica, October 1, 2014 - Government has moved to lay the foundations for the establishment of regulatory regimes to govern the cultivation and use of ganja for medical and scientific purposes, as well as non-medical industrial hemp. This is being effected through draft legislation to amend the Dangerous Drugs Act, where the cultivation and other activities involved in the production and supply of the plants will be legal under a controlled regime. Minister of Justice, Senator Mark Golding, told press briefing that while the amended law will observe Jamaica’s anti-narcotics obligations, the industries will operate under licence. “It must be emphasized that these proposals must be consistent with the existing requirements of the anti-narcotics treaties to which Jamaica is a party,” Senator Golding said, adding that it is “significant that the regulated utilization of ganja and industrial hemp for the specific purposes is indicated by the 1961 United Nations Single Convention on Narcotic Drugs.” He noted that the UN Convention on Narcotic Drugs permits signatories to take such “legislative and administrative measures as may be necessary…subject to the provisions of this Convention, to limit exclusively to medical and scientific purposes, the production, manufacture, export, import, distribution of trade in, use and possession of drugs.” The Minister, while pointing to hemp industries in the European Union (EU), said the UN Convention “expressly allows the cultivation, processing of cannabis for medical and scientific purposes, subject to the control measures which State parties are obliged to put in place.” A Licensing Authority is to be established to govern the licensing processes for participation in the medicinal ganja industry, while the industrial hemp industry will be similarly subject to a licensing system. The amended Dangerous Drugs Act will enable the making of regulations for the licensing authority. Minister Golding said it will deal with “permits and authorizations for the controlled cultivation, production, processing, possession, transportation, delivery, offering for sale, exporting and importing of ganja for medical and scientific purposes, including research, clinical trials and the manufacture of nutraceuticals and pharmaceuticals.”
Last modified onWednesday, 01 October 2014 17:29
Latest from Calvin G. Brown
- BARBADOS | The time to invest in BPO in the Caribbean is now!
- CARICOM vital to regional development: Grenada’s new envoy
- Russia Calls US Intervention in Venezuela 'Unacceptable'
- JAMAICA | Earnings of US$3.6 Billion Expected from Tourism
- CARICOM again calls for non-intervention and dialogue in Venezuela